The United States has approved the first CAR-T cell therapy for patients with bone marrow cancer

The FDA’s approval is based on the central phase 2 study KarMMa which included 128 patients. The patients in the study received one of three dosage levels ranging from 150 to 450 million T cells. The majority of patients achieved a “quick, deep and sustained response”, Bristol Myers Squibb and Bluebird Bio state in a press release. The response rate was 73%, including a complete response rate of 33%. The median response time was 11 months. The patients lived a median of almost nine months without the disease worsening – a measure called progression-free survival. The patients treated in the study with the highest dose had a response rate of 82%, including a complete response rate of 39%. These patients lived a median of one year without the disease worsening.

One patient in the study died of a severe case of cytokine storm, an immune reaction often associated with CAR-T treatment. Overall, moderate to severe cytokine storms were reported in less than 6% of patients. Three percent of patients reported high-grade neurotoxicity, another side effect often seen in CAR-T therapy.

The study was published in the New England Journal of Medicine in February.

– CAR-T cell therapies have shown a groundbreaking potential for the treatment of blood cancer. We are proud to be able to offer the first CAR-T cell therapy to multiple myeloma patients who have undergone several treatment lines, which provides the opportunity for long-term effect, says Samit Hirawat who is Bristol Myers Squibb’s chief physician.


Get the latest news delivered to your inbox

Follow us on social media networks

PREV In possession of Anderson Torres, Bolsonaro cites PF and PRF and says ‘changes are natural’ | Politics
NEXT – I would not plan for a holiday abroad in June